Chart Patterns and Trends

[Stockz4O]

PYTO NEWS

PhytoMedical Bolsters Cancer Research Following Favorable Results
Monday February 4, 9:15 am ET
Patented anticancer compounds demonstrate special ability to kill multiple human cancer cells; success against often-terminal lung cancer, and brain cancer, an extremely resistant, fatal strain of cancer

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO - News) (FWB: ET6), today announced that favorable research outcomes from ongoing tests have spurred immediate expansion of the Company’s cancer research program, actively working to develop patented, next-generation anticancer compounds targeting multiple human cancer strains.

ADVERTISEMENT
“The results of our ongoing investigation of these patented compounds have been very encouraging, especially when considering that researchers have not only been successful at killing cancer cells from multiple, hard-to-treat cancers, but above all, unlike other studies which simply target cancer cells from animals, these tests have demonstrated our ability to kill cancer cells from humans,” explained Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.

Researchers have recently reported promising results of in vitro studies involving human glioblastoma (brain) and small cell lung cancer cells using bis-acridine compounds. These synthetic bis-acridines have demonstrated significant, favorable activity in killing two difficult-to-treat strains of human cancer cells representative of each of these cancers; DMS-114 small cell lung cancer and SF-295 glioblastoma.

“The promising results of these human cancer cell in-vitro studies have encouraged us to immediately bolster our cancer research initiative,” continued Mr. Wujek.

“Through our expanded research program, scientists will undertake new tests of next-generation variations of our patented anticancer compounds. I also look forward to building on our early success against brain and lung cancer cells by targeting other prevalent and difficult-to-treat strains of human cancer, including both breast and colon cancer.”

PhytoMedical’s Cancer Research: Killing Cancer’s DNA

PhytoMedical is developing a novel class of patented anti-cancer agents that have a ‘cytotoxic’ or poisonous affinity for cancer cells. These new compounds are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new (“daughter”) cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through “intercalation,” a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules (“bis-intercalators”) that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.